Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Harbin Pharmaceutical Group Co (600664.SS) as of Nov 7, 2026 is 12.31. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 10.10 — a change of 21.86% (higher).

EV/EBIT

12.31

YoY

21.86%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Harbin Pharmaceutical Group Co is 2025 12.31 . EV/EBIT (Enterprise Value to EBIT) of Harbin Pharmaceutical Group Co was 2024 10.10 . It decreases by 21.86% higher compared to the previous year.

The Harbin Pharmaceutical Group Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
32.37 CNY
Jan 1, 2020
-9.54 CNY
Jan 1, 2021
14.00 CNY
Jan 1, 2022
12.92 CNY
Jan 1, 2023
13.63 CNY
Jan 1, 2024
10.10 CNY
Jan 1, 2025
12.31 CNY
Jan 1, 2026 (e)
13.63 CNY
The Harbin Pharmaceutical Group Co EV/EBIT history
YEAREV/EBITYoY
est13.63+10.74%
12.31+21.86%
10.10-25.90%
13.63+5.48%
12.92-7.67%
14.00-246.65%
-9.54-129.48%
32.37+89.88%
17.05+24.37%
13.71+52.03%
9.02-25.66%
12.13-54.12%
26.44-46.47%
49.39+274.45%
13.19-39.91%
21.95-8.39%
23.96+5.64%
22.68+55.45%
14.59-57.91%
34.66+220.04%
10.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Harbin Pharmaceutical Group Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Harbin Pharmaceutical Group Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Harbin Pharmaceutical Group Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Harbin Pharmaceutical Group Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Harbin Pharmaceutical Group Co grows earnings faster than its peers.

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

EV/EBIT (Enterprise Value to EBIT) of Harbin Pharmaceutical Group Co is 12.31 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Harbin Pharmaceutical Group Co changed from 10.10 to 12.31, representing a 21.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Harbin Pharmaceutical Group Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Harbin Pharmaceutical Group Co